Routine-dose and High-dose Icotinib in Advanced Non-Small Cell Lung Cancer Patients harboring EGFR Exon 21 L858R Mutation: the Randomized, Phase II, INCREASE Trial.

CONCLUSIONS: High-dose icotinib improved mPFS and ORR in NSCLC patients harboring 21-L858R mutation with acceptable tolerability, which could be a new therapeutic option for this patient population. PMID: 32060099 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32060099?dopt=Abstract

Source: Clinical Cancer Research - February 13, 2020 Category: Cancer & Oncology Authors: Li X, Zhang L, Jiang D, Wang Y, Zang A, Ding C, Zhao M, Su W, Zhang Y, Zhong D, Wu J, Zhang C, An G, Hu X, Cheng G, Wang H, Li Y, He X, Liu J, Liang L, Ding L, Mao L, Zhang S Tags: Clin Cancer Res Source Type: research